The candidate vaccine’s next steps will be going through the FDA’s Biologics License Application process.
|Articles|August 1, 2022
A New CE Session to Check Out
A new CE opportunity that's available on-demand.
Advertisement
About The Session
Incorporating REMS Programs into the Pharmacy Process:
Risk Evaluation and Mitigation Strategy (REMS) programs can be required by the Food and Drug Administration (FDA) for medications with serious safety concerns or adverse effects. Pharmacists and pharmacy technicians need to be familiar with the mandatory components of a medication’s REMS program. Examples of mandatory REMS tasks for pharmacists and pharmacy technicians will be reviewed. Additionally, recently approved medications with REMS in 2021, as well as modified REMS programs, such as pending changes for dispensing clozapine, will be examined.
Subscription to AdvanCE required.
Advertisement
Related to this article
The Milken Institute released survey results alongside new data regarding the need for pharmacists in extending effective GLP-1 care.
Through the ACCESS program, Mark Ey, RPh, notes that pharmacies can now start billing for a variety of services they’ve already been providing.
The medication significantly increased risk of pregnancy loss when compared with macrolide antibiotics, amoxicillin, and topical clindamycin for acne.
In part 3, Rebold explores improving the ART formulary protocol through introducing pharmacist-led transition-of-care services.
Our hosts explore why ketone monitoring matters, what pharmacists should know about Libre Duo, and how patient education can support proactive care management.
Mark Ey, RPh, details the patient-focused factors of the ACCESS to Pharmacy Care Program and the ways in which valued care translates to reimbursement.
A new option for adults who have experienced stroke will now be available to further reduce future risk.
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Adds NAION Eye Risk Warning to All GLP-1 Labels
2
The Pharmacy Model Creating New Billing Pathways, Improved Recognition
3
New Report Finds Pharmacies Key in Long-Term GLP-1 Success
4
Vaxcyte’s VAX-31 Pneumococcal Vaccine Meets All Phase 3 Primary Goals
5